So far, monoclonal Abs targeting PD‐1 or CTLA‐4 are being investigated in several clinical trials for different stages and disease status of patients with HNSCC (Ferris, 2015). This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.